Critical illness Not Applicable
Conditions
Interventions
The patients will be studied once on day 1-2 of ICU admission, and once on day 10-14 (if still in ICU). Blood sampling from patients and healthy volunteers will take place during the night from 21.00
Sponsors
Catholic University Leuven (Katholieke Universiteit Leuven) (Belgium)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients admitted to any of the five intensive care units (ICUs) 2. Older than 18 years 3. Age, gender and BMI matched healthy subjects
Exclusion criteria
Exclusion criteria: 1. Age less than 18 years 2. Pre-existing neurological, psychiatric, metabolic, or endocrine disease 3. Intracranial hypertension 4. Intracranial lesions which could influence the hypothalamus-pituitary axis function 5. Gastrectomy 6. Clinically significant liver failure (prothrombin time 90mg hydrocortisone/day or >18 mg methyl-prednisolone/day), somatostatin, clonidine, dopamine or dopamine antagonist.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentrations of ghrelin and GH will be measured in each sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Information obtained from each patient at baseline 1.1. Demographic 1.2. Diagnostic 1.3. Therapeutic 1.4. Severity of illness (Acute Physiology and Chronic Health Evaluation [APACHE-II]) (Knaus W.A. et al. Critical Care Medicine, 1985, 13:818-829) 2. Evaluation of trends in organ dysfunction (Sepsis-related Organ Failure Assessment score [SOFA]) (Intensive Care Med. 1996,22:707-10) 3. At 06.00h, serum concentrations of the following will be measured: 3.1. Insulin-like growth factor I (IGF-I) 3.2. IGF-binding protein-1 (IGFBP-1) 3.3. IGFBP-3 3.4. The acid-labile subunit (ALS) 3.5. IGFBP-4 3.6. IGFBP-5 3.7. Insulin 3.8. Leptin 3.9. TSH 3.10. Cortisol 3.11. Adrenocorticotrophic Hormone (ACTH) | — |
Countries
Belgium
Outcome results
None listed